The efficacy of CP22 in epithelial ovarian cancer cell lines and in vivo patient-derived xenografts validates the ability of small-molecule inhibitors to successfully target the ILK pathway in ovarian cancer and warrants further study. Here, ILK is linked to ovarian carcinoma.